FLT3 and acute myeloid leukemia: Accordingly, few TKIs disrupting the oncogenic signaling initiated by FLT3 are already FDA-approved (midostaurin and gilteritinib), and several others are under development, offering promising therapeutic strategies for patients with FLT3-ITDMUT AML [44].